These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 2531804)

  • 1. Dose-response relationship in intoxication by the pyrrolizidine alkaloid monocrotaline.
    Shubat PJ; Hubbard AK; Huxtable RJ
    J Toxicol Environ Health; 1989; 28(4):445-60. PubMed ID: 2531804
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pulmonary vasculature in monocrotaline-induced hypertensive rats on magnesium therapy.
    Mathew R; Gloster ES; Altura BT; Altura BM
    Microcirc Endothelium Lymphatics; 1990; 6(4-5):267-83. PubMed ID: 2149161
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Na+/K(+)-adenosine triphosphatase activity of pulmonary arteries after intoxication with the pyrrolizidine alkaloid, monocrotaline.
    Shubat PJ; Bowers RJ; Huxtable RJ
    J Pharmacol Exp Ther; 1990 Jan; 252(1):70-6. PubMed ID: 2153811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum copper concentration as an index of cardiopulmonary injury in monocrotaline-treated rats.
    Molteni A; Ward WF; Ts'ao CH; Fitzsimons EJ
    Ann Clin Lab Sci; 1988; 18(6):476-83. PubMed ID: 3149170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pulmonary toxicity of monocrotaline differs at critical periods of lung development.
    Todd L; Mullen M; Olley PM; Rabinovitch M
    Pediatr Res; 1985 Jul; 19(7):731-7. PubMed ID: 3161000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strain differences in pulmonary hypertensive response to monocrotaline alkaloid and the beneficial effect of oral magnesium treatment.
    Mathew R; Altura BT; Altura BM
    Magnesium; 1989; 8(2):110-6. PubMed ID: 2526910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocrotaline pyrrole-induced cardiopulmonary toxicity is not altered by metergoline or ketanserin.
    Ganey PE; Sprugel KH; Hadley KB; Roth RA
    J Pharmacol Exp Ther; 1986 Apr; 237(1):226-31. PubMed ID: 2937908
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of methylprednisolone on monocrotaline-induced pulmonary vascular disease and right ventricular hypertrophy.
    Langleben D; Reid LM
    Lab Invest; 1985 Mar; 52(3):298-303. PubMed ID: 3156262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Altered pulmonary vascular smooth muscle responsiveness in monocrotaline-induced pulmonary hypertension.
    Altiere RJ; Olson JW; Gillespie MN
    J Pharmacol Exp Ther; 1986 Feb; 236(2):390-5. PubMed ID: 3080584
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Effects of various doses of monocrotaline administration on the development of pulmonary hypertension and its regression in rats].
    Kakusaka I; Kaneko N; Kiyatake K; Fujita A; Suzuki A; Nakano K; Okada O; Sugita T; Watanabe S; Kuriyama T
    Nihon Kyobu Shikkan Gakkai Zasshi; 1989 Jan; 27(1):51-6. PubMed ID: 2501548
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differentiation of the cardiac and pulmonary toxicity of monocrotaline, a pyrrolizidine alkaloid.
    Lafranconi WM; Duhamel RC; Brendel K; Huxtable RJ
    Biochem Pharmacol; 1984 Jan; 33(2):191-7. PubMed ID: 6200114
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Attenuation of compensatory right ventricular hypertrophy and heart failure following monocrotaline-induced pulmonary vascular injury by the Na+-H+ exchange inhibitor cariporide.
    Chen L; Gan XT; Haist JV; Feng Q; Lu X; Chakrabarti S; Karmazyn M
    J Pharmacol Exp Ther; 2001 Aug; 298(2):469-76. PubMed ID: 11454907
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of morphologic, hemodynamic, and biochemical changes in lungs of rats given monocrotaline pyrrole.
    Reindel JF; Ganey PE; Wagner JG; Slocombe RF; Roth RA
    Toxicol Appl Pharmacol; 1990 Nov; 106(2):179-200. PubMed ID: 2256110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monocrotaline-induced cardiopulmonary injury in rats. Modification by the neutrophil elastase inhibitor SC39026.
    Molteni A; Ward WF; Ts'ao CH; Hinz JM
    Biochem Pharmacol; 1989 Aug; 38(15):2411-9. PubMed ID: 2547380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventive effects of raloxifene, a selective estrogen receptor modulator, on monocrotaline-induced pulmonary hypertension in intact and ovariectomized female rats.
    Nishida M; Hasegawa Y; Tanida I; Nakagawa E; Inaji H; Ohkita M; Matsumura Y
    Eur J Pharmacol; 2009 Jul; 614(1-3):70-6. PubMed ID: 19379725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of dietary restriction and altered sodium intake on the cardiopulmonary toxicity of monocrotaline pyrrole.
    Ganey PE; Fink GD; Roth RA
    Toxicol Appl Pharmacol; 1985 Mar; 78(1):55-62. PubMed ID: 2930913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lung vessel leak precedes right ventricular hypertrophy in monocrotaline-treated rats.
    Sugita T; Hyers TM; Dauber IM; Wagner WW; McMurtry IF; Reeves JT
    J Appl Physiol Respir Environ Exerc Physiol; 1983 Feb; 54(2):371-4. PubMed ID: 6219974
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alteration of monocrotaline pyrrole-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulphinpyrazone.
    Hilliker KS; Roth RA
    Br J Pharmacol; 1984 Jun; 82(2):375-80. PubMed ID: 6234044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The platelet thromboxane inhibitor, dazmegrel, does not reduce monocrotaline-induced pulmonary hypertension.
    Langleben D; Carvalho AC; Reid LM
    Am Rev Respir Dis; 1986 May; 133(5):789-91. PubMed ID: 3085563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An evaluation of procoagulant activity in the peripheral blood of rats treated with monocrotaline pyrrole.
    Schultze AE; Wagner JG; Roth RA
    Toxicol Appl Pharmacol; 1991 Jul; 109(3):421-31. PubMed ID: 1830177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.